Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

QIAGEN

QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.

QIAGEN Partners Inovio to Develop Companion Diagnostics

Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.

Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates

More revenue, more cash, lower expenses, and a lot of pipeline activity were the major stories for the biotech in Q1.

What You'll Want to Know About Inovio Pharmaceuticals' Q1 Earnings Update

Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Q1 2019 Results - Earnings Call Transcript

Inovio's dBiTEs is a promising anti-cancer technology platform in pre-clinical development.

Inovio's dBiTEs Technology Data Adds To Buy Conviction

Inovio (INO) reported earnings 30 days ago. What's next for the stock?

Inovio (INO) Up 10.7% Since Last Earnings Report: Can It Continue?

Inovio receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.

Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457

Inovio is a problem child with a story. It is shooting for gold with slowly developing trials for high value therapies.

Inovio: Good Times Ahead?

Shares of Inovio Pharmaceuticals Inc. rose 9% in premarket trade Thursday.

Inovio Pharmaceuticals stock up 9% after company announces positive data from Phase 1 trial of Ebola vaccine

Inovio's most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.

Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

Galmed Pharmaceuticals

La Jolla Pharmaceutical

MannKind

Viking Therapeutics

This off-the radar pick could be poised to be a huge winner. Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company.

5 Sizzling Biotech Stocks Under $10 With Gigantic Upside Potential

Geron

Verastem

These three penny stocks have enormous upside potential, but they each come with a hefty dose of risk.

3 Penny Stocks That Could Make You Rich -- or Regretful

News for Inovio Pharmaceuticals Stock (INO)